Biotech Holders Trust Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 39 Posts
1 2 3
Moderna ETFs To Shine On Vaccine News As Outbreak Worsens
Article By: Zacks Investment Research Wednesday, November 18, 2020 4:55 AM EST
The first company to begin human clinical trials of its coronavirus vaccine candidate in the United States — Moderna — has once again come up with encouraging study data relating to mRNA-1273.
In this article: IBB, BBH, XBI, BTEC, IDNA, GERM, MRNA
Read
Will Novavax ETFs Gain On Coronavirus Vaccine Progress?
Article By: Zacks Investment Research Saturday, September 5, 2020 5:50 PM EST
Novavax (NVAX) is a formidable name in the list of companies who are working on a vaccine. The company’s shares have gained 2487.4% this year. Let’s look at ETFs with the highest exposure to Novarax that can gain on the positive development,
In this article: BBH, PTH, IBB, DWAS, GERM
Read
Moderna ETFs To Gain On New Positive COVID-19 Vaccine Data
Article By: Zacks Investment Research Friday, August 28, 2020 6:31 PM EST
The competition to come up with a coronavirus vaccine is opening up near-term opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to Moderna.
In this article: IBB, BBH, XBI, MRNA, CNCR, BTEC, IDNA, GERM
Read
Biotech ETFs To Gain As Coronavirus Vaccine Hopes Strengthen
Article By: Zacks Investment Research Sunday, July 5, 2020 1:58 PM EST
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments. Therefore, we discuss a few ETFs that provide exposure to the biotech sector:
In this article: IBB, BBH, FBT, XBI, ARKG Also: AZN, JNJ, PFE, MRNA
Read
Moderna - A Step Closer To Coronavirus Vaccine: ETFs To Gain
Article By: Zacks Investment Research Sunday, June 14, 2020 3:44 PM EST
The first company to start human clinical trials of its coronavirus vaccine candidate in the United States — Moderna — has informed that it is on schedule to initiate the final-stage clinical trial by July.
In this article: AZN, JNJ, BBH, MRNA, CNCR, IDNA Also: IBB, XBI
Read
Race For Coronavirus Vaccine Heats Up: Biotech ETFs To Gain
Article By: Sweta Killa Wednesday, May 27, 2020 11:34 AM EST
Given rising spending on drugs and healthcare all over the world, investors should tap the opportune moment by investing in the biotech sector.
In this article: GNOM, IBB, BBH, XBI, BBC, ARKG Also: GSK, MRK, PFE, MRNA
Read
Moderna Soars: Biotech ETFs In Focus
Video By: Neena Mishra Monday, May 18, 2020 1:42 PM EST
Instead of trying to pick winners from the virus, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and healthcare all over the world.
In this video: IBB, BBH, XBI, MRNA Also: JNJ, PFE
Watch
Are Biotech ETFs In Trouble As Coronavirus Dims Guidance?
Article By: Zacks Investment Research Saturday, May 9, 2020 7:49 PM EST
Although the coronavirus seems to be opening up opportunities for biotech companies, it is dampening their guidance as well. Despite impressive results, most of these biotechs have been seeing declining share prices since the earnings releases.
In this article: ALXN, IBB, AMGN, BIIB, GILD, BBH, XBI
Read
Coronavirus Makes Biotech ETFs Red Hot
Article By: Sweta Killa Tuesday, April 21, 2020 10:40 PM EST
Biotech ETFs are surging with many hitting new 52-week highs lately.
In this article: IBB, BBH, FBT, ARKG, IEIH Also: PFE, REGN, AMGN, MRNA
Read
May's Best And Worst Performers... Usually
Article By: BigTrends Wednesday, May 1, 2019 8:30 AM EST
Here's a look at the industries and groups most like to move the most this month, for better or for worse.
In this article: BBH, XLF Also: AVP, NUS
Read
Bristol-Myers To Acquire Celgene, Puts Healthcare ETFs In Focus
Article By: Sweta Killa Thursday, January 3, 2019 11:00 PM EST
The healthcare space is witnessing a wave of mergers and acquisitions, which could change the landscape of the healthcare business.
In this article: BMY, IBB, CELG, BBH, IHE, PJP, IEIH Also: BLUE
Read
Biotech ETFs In Focus On String Of Q3 Earnings Beat
Article By: Zacks Investment Research Thursday, November 1, 2018 6:57 PM EST
Though the biotech sector is down in October, it shows promise for the long-term due to a wave of mergers & acquisitions and a positive regulatory backdrop.
In this article: IBB, BBH, FBT Also: AMGN, GILD, BIIB, ALXN
Read
Biotech ETFs In Focus On String Of Q2 Earnings Beats
Article By: Zacks Investment Research Sunday, August 12, 2018 4:27 PM EST
The biotech sector has been performing remarkably well driven by a wave of mergers and acquisitions, new tax legislation, and a positive regulatory backdrop. Strong Q2 earnings results have added to the strength as biotech giants topped estimates.
In this article: IBB, AMGN, GILD, BBH, FBT, ALXN, BIIB
Read
Three ETFs To Watch On Biotech Earnings
Article By: Zacks Investment Research Monday, February 12, 2018 5:33 AM EST
The earnings season is off to a flying start, owing to a slew of upbeat economic data, strong corporate performance, and President Donald Trump's tax reform signed into law.
In this article: BIB, IBB, BBH Also: ALXN, AMGN, BIIB, GILD
Read
4 ETFs Set To Surge In Q4 Earnings
Article By: Sweta Killa Monday, January 15, 2018 1:51 PM EST
The fourth-quarter earnings season is expected to be strong, with earnings growth likely to pick up and continue accelerating after dipping in the preceding quarter.
In this article: BBH, PMR, PXE, ITB Also: TOL, LOW, DHI, HD, EOG, OXY, CLR, COP, BBY, DLTR, WBA, CELG, AMGN, ILMN, INCY
Read
3 ETFs To Watch On Biotech Earnings
Article By: Zacks Investment Research Sunday, October 29, 2017 5:13 PM EST
The earnings season is off to a flying start with equity markets. However, the performance has been a mixed bag for biotech companies with some beating market expectations, while a few failed to do so.
In this article: ALXN, AMGN, BIIB, BIB, IBB, BBH, GILD
Read
1 to 16 of 39 Posts
1 2 3